Literature DB >> 22835263

A comparative study of clinical characteristics, work-up, treatment, and association to malignancy in dermatomyositis between two tertiary skin centers in the USA and Singapore.

Gil Yosipovitch1, Audrey Tan, Katherine LoSicco, Catherine G Manabat, Ajith Kannagra, Christie Carroll, Yiong Huak Chan, Patricia Ng, Joseph Jorizzo.   

Abstract

BACKGROUND: To date, no study has compared the clinical characteristics, malignancy associations, and treatment of dermatomyositis in predominantly Caucasian vs. Asian populations.
MATERIALS AND METHODS: This prospective study was conducted to compare clinical characteristics of dermatomyositis, its relationship to malignancy, and treatment between two tertiary medical centers in the USA and Singapore. A total of 19 newly-diagnosed patients in the USA and 15 patients in Singapore were enrolled. Dermatomyositis or amyopathic dermatomyositis were diagnosed based on clinical assessment, skin and muscle biopsies, and muscle testing.
RESULTS: Ninety-five percent of patients in the USA group were of Caucasian descent, while 93% of patients in the Singapore group were of Chinese descent. Both groups were predominantly female. Pruritus was the most common initial symptom reported in both groups, while periungual erythema and Gottron's papules were the most common skin presentations. Heliotrope eruption was more common in the Singapore group, occurring in 80% of patients vs. 32% of patients in the USA group (P = 0.007). Three patients in the Singapore group developed a malignancy, with two of these patients having nasopharyngeal carcinoma. None of the USA patients developed malignancies in a follow- up period of 2-5 years. Immunosuppressive steroid sparing therapy with hydroxychloroquine was more frequently used in Singapore, while topical tacrolimus was more frequently used in the USA.
CONCLUSION: The clinical presentations of dermatomyositis vary among different ethnic populations. Chinese patients with dermatomyositis have a significant risk for nasopharyngeal carcinoma.
© 2012 The International Society of Dermatology.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22835263     DOI: 10.1111/j.1365-4632.2011.05449.x

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  8 in total

1.  Dermatomyositis: analysis of 109 patients surveyed at the Hospital das Clínicas (HCFMUSP), São Paulo, Brazil.

Authors:  Luciena Cegatto Martins Ortigosa; Vitor Manuel Silva dos Reis
Journal:  An Bras Dermatol       Date:  2014 Sep-Oct       Impact factor: 1.896

2.  Update on Epidemiology and Clinical Assessment Tools of Cutaneous Lupus Erythematosus and Dermatomyositis.

Authors:  Yunyoung C Chang; Victoria P Werth
Journal:  Curr Dermatol Rep       Date:  2013-01-24

Review 3.  IL-31 Inhibition as a Therapeutic Approach for the Management of Chronic Pruritic Dermatoses.

Authors:  Youkyung S Roh; Justin Choi; Nishadh Sutaria; Micah Belzberg; Madan M Kwatra; Shawn G Kwatra
Journal:  Drugs       Date:  2021-04-21       Impact factor: 9.546

4.  Paraneoplastic Dermatomyositis in Association with Poorly Differentiated Esophageal Carcinoma - A Rare Association and a Brief Review of Literature.

Authors:  Swaroopa Subhash; S Pradeep Nair; K Abdul Samad; Sheena Ann Simon; Mini Gomathy
Journal:  Indian J Dermatol       Date:  2020 Jan-Feb       Impact factor: 1.494

Review 5.  Pruritus in autoimmune connective tissue diseases.

Authors:  Hee Joo Kim
Journal:  Ann Transl Med       Date:  2021-03

Review 6.  Autoimmune Connective Tissue Diseases-Related Pruritus: Proper Diagnosis and Possible Mechanisms.

Authors:  Lai-San Wong; Yu-Ta Yen
Journal:  Diagnostics (Basel)       Date:  2022-07-21

7.  Increased Epidermal Nerve Growth Factor without Small-Fiber Neuropathy in Dermatomyositis.

Authors:  Lai-San Wong; Chih-Hung Lee; Yu-Ta Yen
Journal:  Int J Mol Sci       Date:  2022-08-12       Impact factor: 6.208

8.  Characteristics and predictors of malignancy in dermatomyositis: Analysis of 239 patients from northern China.

Authors:  Ying Liu; Lulu Xu; Hongliang Wu; Na Zhao; Yanchun Tang; Xiaoping Li; Ying Liang
Journal:  Oncol Lett       Date:  2018-09-05       Impact factor: 2.967

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.